Clinical trials
Refractory clinical trials
Below are recruiting refractory clinical trials, each written for real people, not researchers. We’re tracking 1,200 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07263906RecruitingPhase 1
LILRA6 car-t therapy for resistant or relapsed aml
This early-phase trial tests a new cell therapy (CAR-T) that targets a protein called LILRA6 on leukemia cells. It's designed for people whose acute myeloid leukemia (AML) has come back or hasn't responded to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT03506893Recruiting
Alfapump device to reduce stubborn belly fluid in liver disease
This study looks at whether placing an Alfapump under the skin can better manage “refractory ascites,” which is stubborn belly fluid buildup in people with cirrhosis. It also evaluates the medical and economic impact of this care, and who benefits most.
AmiensAges 18 years+ - NCT07250269RecruitingPhase 1
CAR-T therapy for AL amyloidosis
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
BeijingAges 18 years+ - NCT07258511RecruitingPhase 3
Comparing a new drug to Teclistamab for advanced multiple myeloma
This study tests a new experimental drug (JNJ-79635322) compared to another targeted immunotherapy (Teclistamab) for people with multiple myeloma that has returned or not responded after several prior treatments.
Phoenix, ArizonaAges 18 years+ - NCT07255898RecruitingPhase 1
Study of BL-M24D1 for multiple myeloma and other blood cancers
This trial tests a new drug, BL-M24D1, for people with multiple myeloma or other blood cancers that have come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
Chengdu, SichuanAges 18 years+ - NCT07252531Recruiting
BrioVAD heart pump study for advanced heart failure
This trial tests a new heart pump (BrioVAD) for people with very advanced heart failure. It aims to help those who are not getting better with standard treatments or who need extra support like IV medicines or a balloon pump.
RotterdamAges 18 years+ - NCT07253259RecruitingEarly Phase 1
Cell therapy for hard-to-treat chronic graft-versus-host disease
This study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with at least two previous treatments. The therapy is given as an injection and aims to help control the immune system reaction that causes cGVHD.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07257588Enrolling by invitation
Hyperbaric oxygen for severe ulcerative colitis
This study tests whether adding hyperbaric oxygen therapy—breathing pure oxygen in a pressurized chamber—to standard care can help people with a severe flare of ulcerative colitis (a type of inflammatory bowel disease). It may reduce inflammation and speed up recovery.
Xi'an, ShaanxiAges 18 years+ - NCT06901817RecruitingPhase 2
Study of pemetrexed plus nivolumab for lung cancer that has spread to the lining of the brain
This trial tests a combination of two drugs, pemetrexed and nivolumab, given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (non-squamous non-small cell) that has spread to the lining of the brain and has not responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07248176Recruiting
Universal CAR-T therapy for multiple myeloma
This trial tests a universal CAR-T cell therapy (made from donated cells) for multiple myeloma that has come back after at least two prior treatments. It may be an option if your cancer cells have a specific marker called BCMA and you have not had certain prior therapies.
ShanghaiAges 18 years+ - NCT07249073RecruitingEarly Phase 1
Dual-target CAR-T for relapsed/refractory myeloma
This trial tests a new CAR-T cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It may help patients whose myeloma has come back or stopped responding to previous treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06794008RecruitingPhase 2
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Beijing, Beijing MunicipalityAges 18–65 - NCT07230600RecruitingPhase 1
Stem cell therapy for thin uterine lining or scarring
This trial tests a new treatment for people with a thin uterine lining or uterine scarring that hasn't responded to other stem cell therapy. It might help improve the lining so pregnancy is possible.
Nanjing, JiangsuAges 22–45 - NCT07233642RecruitingPhase 1
Fast CD19 CAR-T therapy for lupus not helped by standard treatment
This trial tests a quick-made CAR-T cell therapy for children and adults with active lupus who haven't gotten better with standard drugs. The goal is to see if targeting a protein called CD19 on certain immune cells can calm the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT05995951Recruiting
Deep brain stimulation for severe OCD
This trial tests whether deep brain stimulation (a surgical implant that sends electrical pulses to part of your brain) can help people with severe obsessive-compulsive disorder (OCD) that has not improved with standard treatments.
Petah TikvaAges 18–75 - NCT07225972RecruitingPhase 3
Immune cells from a family donor for stubborn virus infections after stem cell transplant
This trial is testing whether giving special immune cells from a family donor (called CTLs) along with regular antiviral medicine is better than regular medicine alone for people who have a stubborn adenovirus or cytomegalovirus infection after a stem cell transplant.
Valhalla, New YorkAges 1 day–30 years - NCT06911333RecruitingPhase 1/Phase 2
A new drug for advanced solid tumors that have stopped responding to treatment
This trial tests a new drug called AD1208 for people with advanced solid tumors that have grown despite previous treatments. The goal is to see if the drug can help where other options no longer work or are not suitable.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07222761RecruitingPhase 3
Comparing new treatments for relapsed multiple myeloma
This trial tests if a new medicine called linvoseltamab, alone or combined with carfilzomib, works better than the usual treatments for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies.
Atlanta, GeorgiaAges 18 years+ - NCT07227311RecruitingPhase 2
Belantamab mafodotin combinations for relapsed multiple myeloma
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
Los Alamitos, CaliforniaAges 18 years+ - NCT06911710RecruitingPhase 1/Phase 2
Car-T therapy for relapsed blood cancers
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06914037RecruitingPhase 1
CHT101 for CD70-positive blood cancers
This trial tests a new drug, CHT101, for people with certain blood cancers that have not responded to prior treatments. It is specifically for cancers that test positive for a protein called CD70.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07219407RecruitingPhase 2
Long-term safety study of RAP-219 for focal seizures
This study tests the long-term safety and effectiveness of RAP-219, an investigative medication for focal epilepsy. It is for people who already completed an earlier study of RAP-219, have a type of epilepsy that doesn't respond to standard medicines, and use a surgically implanted brain device (RNS system) to help manage seizures.
Boise, IdahoAges 18–70 - NCT07220876Recruiting
VisiPlate implant for hard-to-control open-angle glaucoma
This trial tests a new device called VisiPlate that is placed in the eye to help lower pressure for people with hard-to-control open-angle glaucoma. It may be an option if standard treatments haven't worked well enough.
Glendale, ArizonaAges 45 years+ - NCT07219563RecruitingPhase 1
Alnuctamab for hard-to-treat lupus (LATTE Study)
This trial tests a new drug called alnuctamab for people with lupus (SLE) that hasn't responded to multiple standard treatments. It aims to see if targeting certain immune cells can reduce lupus activity.
New York, New YorkAges 18–60
Hear when a new Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory?
- Yes. Clin2 currently lists 1,200 recruiting refractory studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.